Community/Retail

The FDA lifts the black box warning on hormone replacement therapy, empowering women with new options for managing menopause symptoms.

Recent analysis reveals no significant link between maternal acetaminophen use and increased autism or ADHD risk, challenging previous health claims.

Inclisiran significantly enhances LDL-C goal attainment in post-acute coronary syndrome patients, improving lipid management outcomes.

A bidirectional relationship was observed between long COVID and cardiovascular disease in survey results presented at IDWeek.

New data from AHA 2025 demonstrate the benefits of pharmacist-led hypertension management in reducing hemoglobin A1c (HbA1c) and blood pressure in minority patients with type 2 diabetes.

Explore the critical role of pharmacists in improving cardiovascular health and addressing mortality trends in underserved communities.

A new drug, DR10624, shows promise in reducing triglycerides and liver fat, offering hope for patients with severe hypertriglyceridemia and fatty liver disease.

Shoa Clarke, MD, PhD, discusses the need for improved cholesterol testing and treatment in young adults, emphasizing the vital role of primary care teams and pharmacists in early intervention and adherence.

Explore the link between chronic kidney disease and cardiovascular risk, highlighting the importance of GFR and albuminuria in patient care.

Experts at AHA 2025 advocate for integrated care in T2D and CKD, emphasizing cardiovascular risk management to enhance patient outcomes.

Discover how Sotatercept impacts cardiovascular health and its potential benefits for patients with pulmonary arterial hypertension (PAH) in this insightful article.

Pharmacists play a vital role in managing cardiovascular health, addressing medication adherence, and educating patients, said Zia Ul Haq, MPH, MBBS.

Consistent use of continuous glucose monitoring (CGM) significantly improves glycemic control in adults with type 2 diabetes (T2D).

Maternal type 1 diabetes may influence children's DNA, potentially reducing their risk of developing islet autoimmunity.

Knowledge of serotype prevalence and virulence can optimize the management of community-acquired pneumonia.

Maintaining cardiovascular health significantly reduces dementia risk in adults with type 2 diabetes, highlighting the heart-brain connection for cognitive protection.

The move continues the push towards most favored nation (MFN) status, lowering the prices of glucagon-like peptide-1 (GLP-1s) drugs for Medicare recipients.

Moderate to severe obstructive sleep apnea significantly increases the risk of cerebral microbleeds.

A genomic screening initiative identified patients harboring a familial hypercholesterolemia genetic variation and directed them toward LDL-C-lowering therapies, inducing meaningful reductions.

Combining GLP-1 RA therapy with healthy lifestyle habits significantly reduces cardiovascular risk in type 2 diabetes patients, enhancing heart health outcomes.

As an adjunct to depression treatment, lumateperone reduced depressive symptoms and improved quality of life.

Enfortumab vedotin-ejfv has transformed treatment in locally advanced and metastatic urothelial carcinoma from decades-long platinum-based chemotherapy to the new standard of care combination of antibody-drug conjugate and PD-1/PD-L1 inhibitor.

Discover the importance of early screening for type 1 diabetes and how it can prevent life-threatening complications.

Low-dose aspirin significantly reduces heart attack, stroke, and death risks in adults with type 2 diabetes and elevated cardiovascular risk.

Oral semaglutide shows promise in enhancing glucose control and reducing cardiovascular risks.

Razumab, a ranibizumab biosimilar, shows comparable efficacy to its innovator counterpart in treating myopic choroidal neovascular membrane (mCNVM), offering a cost-effective solution.

Linaclotide has been approved to treat patients 7 years and older with irritable bowel syndrome with constipation, becoming the first treatment for this indication in this age group.